Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Unknown 110 enrolled Taizhou Hanzhong Biomedical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Timeline

Start: 2020-09-25
Primary completion: 2022-12-01
Completion: 2023-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pucotenlimab	Monoclonal antibody	200 mg	Intravenous

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Summary

Timeline

Drugs

Indications